Efficacy of Using Solum IV and BMC With GFC in TLIF

Launched by SETON HEALTHCARE FAMILY · Jul 18, 2017

Keywords

ClinConnect Summary

This is a prospective, single-center clinical study. Ten patients will be enrolled and undergo an TLIF with a spinal fixation system and receive Solum IV (Celling Biosciences) and patient's BMC with GFC.

The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentr...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject is skeletally mature and older than 18 years of age
• • 2. One and contiguous 2 or 3 level primary lumbar fusions.
• 3. L1 to S1 with a primary diagnosis of one or more of the following:
• • 1. Degenerative disc disease,
• • 2. Isthmic-lytic spondylolisthesis,
• • 3. Degenerative spondylolisthesis
• • 4. Spinal stenosis.
• • 4. Subject has received conservative (non -surgical treatment for back pain for a minimum of 6 months and is unresponsive
• • 5. Subject understand the conditions of enrollment and is willing to sign and date the informed consent form
• • 6. Subject agrees to comply with study visits
• • -
• Exclusion Criteria:
• • 1. Previous bilateral Iliac Crest Bone Graft (ICBG) harvest
• • 2. Previous instrumented fusion at the same or adjacent level
• • 3. Active systemic infection, infection localized to the site of implantation or at aspiration site
• • 4. Vulnerable patients
• • 1. Nursing home residents
• • 2. Prisoners
• • 3. Other institutionalized persons
• • 4. Persons with decisional incapacity
• • 5. Pregnant women or interested in becoming pregnant in the next 12 months
• • 6. Subjects with certain autoimmune diseases (such as lupus)
• • 7. Subject has progressive neuromuscular disease
• • 8. Active hepatitis, AIDS, ARS or is HIV positive
• • 9. Syringomyelia at any spinal levels
• • 10. Any other condition that would interfere with the subject self-assessment of pain, function or quality of life
• • 11. Subjects with multiple allergies
• • 12. Subjects with any history of cancer (except for basal cell carcinoma of the skin)
• • 13. Significant osteoporosis
• • 14. Subject is younger than or equal to 18 years of age
• • 15. Subjects with a BMI of 40 or greater
• • 16. Subject has diabetes mellitus requiring daily insulin management
• • 17. Subject has allergy to implant materials (such as titanium, titanium alloy)
• • 18. Subject has primary or metastatic tumors involving the spine
• • 19. Subject is participating in another investigational study for a similar purpose
• • 20. Subject has a history of significant mental illness or mental incapacity
• • 21. Subject is currently smoker and will not cease smoking from the time of study enrollment up through 3 months post-operatively, nicotine users for whom post-operative bone stimulation would be prescribed, or has a recent history of alcohol or other substance abuse within the past 2 years
• • 22. Subject is receiving workers compensation
• • 23. Absence of English language reading or writing skills
• • -